Avalo Therapeutics (AVTX) Net Income towards Common Stockholders (2014 - 2026)

Avalo Therapeutics (AVTX) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$19.6 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 49.29% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.7 million (down 216.06% YoY) and the FY2025 annual result came in at -$78.3 million, down 122.78% from the prior year.
• Net Income towards Common Stockholders eased to -$19.6 million in Q1 2026, from -$13.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
• A 4-year average of -$12.7 million and a median of -$13.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 1301.79% in 2024, down 1118.38% in 2024.
• Tracing AVTX's Net Income towards Common Stockholders over 4 years: stood at -$8.2 million in 2023, then sank by 332.65% to -$35.3 million in 2024, then surged by 61.18% to -$13.7 million in 2025, then plunged by 43.08% to -$19.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$19.6 million (Q1 2026), -$13.7 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.